Publications

1. In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time-domain autofluorescence decoupling, fluorophore quantification, and localization. McCormack E, Micklem DR, Pindard LE, Silden E, Gallant P, Belenkov A, Lorens JB, Gjertsen BT. Mol Imaging. 2007 May-Jun;6(3):193-204.PMID: 17532885

2. Expanding the spectrum of genetic elements transferable by retroviral vectors. Blø M, Bogenberger JM, Swift SE, Micklem DR, Lorens JB. DNA Cell Biol. 2007 Nov;26(11):773-9.PMID: 17824835

3. MicroRNAs in tumorigenesis. Skaftnesmo KO, Prestegarden L, Micklem DR, Lorens JB. Curr Pharm Biotechnol. 2007 Dec;8(6):320-5. Review.PMID: 18289039

4. RNAi screening for therapeutic targets in human malignancies. Micklem DR, Lorens JB. Curr Pharm Biotechnol. 2007 Dec;8(6):337-43. Review.PMID: 18289042

5. Enhanced gene expression from retroviral vectors. Blø M, Micklem DR, Lorens JB. BMC Biotechnol. 2008 Feb 25;8:19.PMID: 18298815

6. Mural cell associated VEGF is required for organotypic vessel formation. Evensen L, Micklem DR, Blois A, Berge SV, Aarsaether N, Littlewood-Evans A, Wood J, Lorens JB. PLoS One. 2009 Jun 4;4(6):e5798.PMID: 19495422

7. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, Micklem DR, Ruurs P, Sylvain C, Lu Y, Shenk KD, Bennett MK. Blood. 2009 Oct 15;114(16):3439-47. Epub 2009 Aug 11.PMID: 19671918

8. A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery. Evensen L, Micklem DR, Link W, Lorens JB. Cytometry A. 2010 Jan;77(1):41-51.PMID: 19834964

9. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, Micklem DR, Akslen LA, Glackin C, Lorens JB. Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9. Epub 2009 Dec 28.PMID: 20080645

10. Efficient in vivo vascularization of tissue-engineering scaffolds. Hegen A, Blois A, Tiron CE, Hellesøy M, Micklem DR, Nör JE, Akslen LA, Lorens JB. J Tissue Eng Regen Med. 2010 Sep 23. [Epub ahead of print]PMID: 20865694

11. Imaged-based high-throughput screening for anti-angiogenic drug discovery. Evensen L, Link W, Lorens JB. Curr Pharm Des. 2010;16(35):3958-63.PMID: 21158729

12. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB, Ivaska J. Oncogene. 2010 Nov 8. [Epub ahead of print]PMID: 21057535

13. Synthesis and biological evaluation of new camptothecin derivatives obtained by modification of position 20. Riva E, Comi D, Borrelli S, Colombo F, Danieli B, Borlak J, Evensen L, Lorens JB, Fontana G, Gia OM, Via LD, Passarella D. Bioorg Med Chem. 2010 Dec 15;18(24):8660-8. Epub 2010 Oct 7.PMID: 21071230

14. Isosteric replacement of the Z-enone with haloethyl ketone and E-enone in a resorcylic acid lactone series and biological evaluation. Napolitano C, Natoni A, Santocanale C, Evensen L, Lorens JB, Murphy PV. Bioorg Med Chem Lett. 2010 Dec 24. [Epub ahead of print]PMID: 21273066

15. A novel brain metastases model developed in immunodeficient rats closely mimics the growth of metastatic brain tumours in patients. Wang J, Daphu I, Pedersen PH, Miletic H, Hovland R, Mørk S, Bjerkvig R, Tiron C, McCormack E, Micklem D, Lorens JB, Immervoll H, Thorsen F. Neuropathol Appl Neurobiol. 2011 Feb;37(2):189-205. doi: 10.1111/j.1365-2990.2010.01119.x.PMID: 20819169

16. High content screening: seeing is believing. Zanella F, Lorens JB, Link W. Trends Biotechnol. 2010 May;28(5):237-45. Epub 2010 Mar 24. Review.PMID: 20346526

17. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Stapnes C, Døskeland AP, Hatfield K, Ersvaer E, Ryningen A, Lorens JB, Gjertsen BT, Bruserud O. Br J Haematol. 2007 Mar;136(6):814-28.PMID: 17341267

18. Multiple roles for the receptor tyrosine kinase axl in tumor formation. Holland SJ, Powell MJ, Franci C, Chan EW, Friera AM, Atchison RE, McLaughlin J, Swift SE, Pali ES, Yam G, Wong S, Lasaga J, Shen MR, Yu S, Xu W, Hitoshi Y, Bogenberger J, Nör JE, Payan DG, Lorens JB. Cancer Res. 2005 Oct 15;65(20):9294-303.PMID: 16230391

19. PNAS January 2010: Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, Micklem DR, Akslen LA, Glackin C, Lorens JB. Keystone Symposia: Stem Cells, Cancer and Metastasis, Colorado, March 2011